The efficiency targeting IL-33 (itepekimab) and its receptor (astegolimab) for asthma have been confirmed in clinical trials ( 138 ), while they are failed to reach statistical significance in AD except etokimab (a humanized anti-IL-33 monoclonal antibody).
← all excerpts
The role of ILC2s in asthma combined with atopic dermatitis: bridging the gap from research to clinical practice.
1
—
—